5 Key Takeaways Insights On Alternative Designs To The Traditional 33 Design In Phase 1 Dose Escalation Studies
Article | April 26, 2021 5 Key Takeaways: Insights On Alternative Designs To The Traditional 3+3 Design In Phase 1 Dose Escalation Studies By Abie Ekangaki and Andreas Schreiner Traditionally, Phase 1 trials commonly utilize 3+3 designs to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Studies have shown, however, that two out of three trials employing a 3+3 design failed in identifying the MTD, and better approaches are needed.1 During Premier Research’s recent webinar Alternative Designs to the Traditional 3+3 Design in Phase 1...
Source: clinicalleader.com